Rationale and design of Apo-I Event Reduction in Ischemic Syndromes I (AEGIS-I): A phase 2b, randomized, placebo-controlled, dose-ranging trial to investigate the safety and tolerability of CSL112, a reconstituted, infusible, human apoA-I, after acute myocardial infarction
Titel:
Rationale and design of Apo-I Event Reduction in Ischemic Syndromes I (AEGIS-I): A phase 2b, randomized, placebo-controlled, dose-ranging trial to investigate the safety and tolerability of CSL112, a reconstituted, infusible, human apoA-I, after acute myocardial infarction
Auteur:
Gibson, C. Michael Korjian, Serge Tricoci, Pierluigi Daaboul, Yazan Alexander, John H. Steg, Philippe G. Lincoff, A. Michael Kastelein, John J.P. Mehran, Roxana D'Andrea, Denise Merkely, Bela Zarebinski, Maciej Ophius, Ton Oude Harrington, Robert A.